IMUGENE CHART. TA only, page-31475

Not a reflection of IMU (though selling of production facility may hint that we are bit far away from realizing the production capabilities of drugs, but that very pessimistic of me ), but this is the result of US Fed not pivoting towards rate cuts, we will live with highr interest rate scenario atleast for this year and borrowing becomes very costly that means small biotech like IMU will bear the brunt (now think why IMU offloaded the production unit to save 36 mil and change, because they would not have to borrow money at higher rate in near future), so yeah if you can muster to buy at this level or lower, please be my guest.. if not sit tight and nothings changed frrom IMU fundamentals, its still same risk/reward when it went ballistic from 0.019 to 0.6..